Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
Pancreatic Cancer
Genialis, PanCAN partner to validate KRAS biomarker for pancreatic cancer
By
LabPulse.com staff writers
Biomarker company Genialis and the Pancreatic Cancer Action Network (PanCAN) are collaborating to further the validation of the Genialis KrasID biomarker for pancreatic cancer using PanCAN's Know Your Tumor precision medicine service.
June 3, 2024
Immunovia announces positive results for next-gen pancreatic cancer test
By
LabPulse.com staff writers
Diagnostics company Immunovia announced positive results for the newest generation of its pancreatic cancer test from a model-development study, announcing that the test achieved both its primary and secondary endpoints.
April 25, 2024
RNA-seq analysis links protein to spread of pancreatic cancer, reveals potential drug target
By
Nick Paul Taylor
The lack of a genetic driver of metastatic cancer has led researchers to look for other causes of disease progression.
March 23, 2023
Duke University researchers discover biomarkers may identify early pancreatic cancer risk
By
Elissa Wolfson
The researchers identified a set of biomarkers that may help distinguish whether pancreatic cysts are likely to develop into cancer or remain benign.
March 17, 2023
BlueStar Genomics announces rebranding as ClearNote Health, commercialization of pancreatic cancer test
By
LabPulse.com staff writers
The DNA-based blood test is already available in the U.S. through the ClearNote Health physician experience program.
December 22, 2022
Biological Dynamics embarks on clinical utility studies for pancreatic cancer detection assay
By
LabPulse.com staff writers
Biological Dynamics said that it is collaborating with Qure Healthcare and Curta to also evaluate the effects of its pancreatic cancer detection assay on patient outcomes and healthcare economics.
November 23, 2022
University of Pittsburgh NGS test shows high sensitivity in pancreatic cyst study
By
Joseph Constance
By sequencing 22 pancreatic cyst-associated genes, the PancreaSeq test distinguished benign cysts from those that could become cancerous.
October 6, 2022
Immunovia nabs CMS preliminary payment determination
By
LabPulse.com staff writers
The CMS preliminary payment determination implied a test price of $897.
September 26, 2022
Immunovia nabs California approval for pancreatic cancer test
By
LabPulse.com staff writers
The California Department of Public Health has granted Immunovia a clinical and public health laboratory license for the test, Immunovia said Thursday.
August 10, 2022
Guardant highlights data on multicancer test at AACR 2022
By
LabPulse.com staff writers
Guardant Shield analyzes about 20,000 epigenomic markers with a single blood test. In the data presented at AACR 2022, researchers showed the efficacy of Guardant Shield in the detection of four types of early-stage cancers: colorectal, lung, pancreatic, and bladder.
April 12, 2022
AI spots patients at elevated risk for pancreatic cancer
By
Erik L. Ridley
A team of researchers from the U.S. and Denmark used electronic health record (EHR) data from the Danish National Patient Registry to train their algorithm and then tested it on electronic medical records from Mass General Brigham Health Care System in Boston. Their model proved to be highly accurate for predicting patients at high risk for pancreatic cancer on large datasets from both countries.
April 8, 2022
Immunovia touts performance of PanCan-d test in clinical study
By
LabPulse.com staff writers
The test detected pancreatic ductal adenocarcinoma with 99% specificity and 89% sensitivity in stage I/II when excluding individuals with low levels of CA 19-9, an antigen released by pancreatic cancer cells.
February 17, 2022
Page 1 of 2
Next Page
